 |
|
|
| |
ENDURANCE-4: Efficacy and Safety of Glecaprevir/Pibrentasvir (Formerly ABT-493/ABT-530) Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Tarik Asselah1, Christophe Hezode2, Neddie Zadeikis3, Magdy Elkhashab4, Massimo Colombo 5, Rui Marinho6, Kosh Agarwal7, Frederik Nevens8, Ran Liu3, Teresa I. Ng3, Federico Mensa3
1Centre de Recherche sur l'Inflammation, Inserm UMR 1149, Université Paris Diderot, AP-HP Hopital Beaujon, Clichy, France; 2Hopital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France; 3AbbVie Inc., North Chicago, Illinois, United States; 4Toronto Liver Centre, Toronto, ON, Canada; 5Policlinic Hospital IRCCS & University Milan, Italy; 6Hospital S. Maria, Medical School of Lisbon,Portugal; 7Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 8University Hospitals KU, Leuven, Belgium
|
| |
|
|
|
|
|
